Exagen Diagnostics Launches Prognostic Panel

ALBUQUERQUE, N.M., June 9, 2014 /PRNewswire/ -- Exagen Diagnostics, Inc., a leading medical diagnostic company focused in rheumatology, today announced the addition of the Avise SLE Prognostic panel to its testing services.

Designed to supplement the Avise SLE+ Connective Tissue diagnostic, Avise SLE Prognostic is a comprehensive prognostic panel that helps physicians assess potential risk for lupus nephritis, neuropsychiatric lupus, thrombosis and cardiovascular events. The prognostic panel was developed in response to physician requests to help fulfill an unmet need in the rheumatology space.

Lupus is a chronic autoimmune disease that affects 1.5 million Americans, according to the Lupus Foundation of America. These patients, primarily women, can suffer from disease flares that can become destructive to any organ or tissue in the body.

"We are pleased to provide an additional tool to help support physicians with their clinical assessment and treatment of patients. This launch furthers our commitment to providing access to quality serologic testing to all patients. At Exagen, we truly are patient focused and discovery driven," said Ron Rocca, Exagen President and CEO.

About Exagen

Exagen Diagnostics, Inc. is a Patient Focused, Discovery Driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. Committed to Personalized Medicine, our tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. For more information, please visit www.AviseTest.com.